![](https://media.americanpharmaceuticalreview.com/m/28/article/614223.jpg)
Currax Announces New Facility to Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 ...
Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA). The new site doubles the current production capacity of CONTRAVE/MYSIMBA …